Impilo invests in Lowenco – a pioneer in ultra-low temperature storage solutions
Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance market. Following an initial period of product refinement and establishment of go-to-market activities, Lowenco has over the past three years gained significant commercial traction and is today a preferred supplier of sustainable large scale modular ULT storage solutions to several of the largest biotech and pharmaceuticals companies across the globe.
Read moreNews
Scantox Group acquires Gentronix
Today Scantox, together with its majority owner Impilo, finalized the acquisition of Gentronix Ltd, a UK based GLP compliant genetic toxicology Contract Research Organization (“CRO”), well recognized for its high-quality genetic toxicology services and strong scientific engagement.
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.